NDAINTRAVENOUSINJECTABLE
Approved
Aug 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
FLUDEOXYGLUCOSE F18 (fludeoxyglucose f18) by Medica Corp is radiopharmaceutical activity [moa]. First approved in 2005.
Drug data last refreshed 5h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Fludeoxyglucose F18 is a radioactive diagnostic agent used in positron emission tomography (PET) imaging to assess glucose metabolism in the brain. It is indicated for Alzheimer's Disease and Down Syndrome, helping clinicians visualize neurodegeneration and cognitive decline. The radiopharmaceutical works by emitting positrons that allow real-time imaging of metabolic activity in affected brain regions.
LOE Approaching
As a diagnostic radiopharmaceutical approaching loss of exclusivity, career opportunities focus on defending market share against competing imaging modalities and expanding clinical utility in early detection scenarios.
Mechanism of Action
Radiopharmaceutical Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Fludeoxyglucose F18 offers a niche diagnostic career focused on defending market access, strengthening clinical evidence for reimbursement, and positioning the imaging modality in emerging precision neurology workflows. With zero linked jobs currently listed and mature product status, growth is limited but roles exist in medical science liaison, reimbursement strategy, and health economics teams defending diagnostic value against competing modalities.
Diagnostic Product Manager
Worked on FLUDEOXYGLUCOSE F18 at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.